A Study of LY3549492 in Healthy Weight Adult Participants
NCT ID: NCT07085468
Last Updated: 2025-08-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
1 participants
INTERVENTIONAL
2025-07-21
2025-08-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participation in the study will last about 13 months.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity
NCT07232732
A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes
NCT07030868
A Study of LY3541105 in Healthy and Overweight Participants
NCT05380323
A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight
NCT06683508
A Study of LY3841136 in Healthy and Overweight Participants
NCT05295940
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LY3549492 Dose 1
Participants will receive LY3549492 orally
LY3549492
Administered orally
LY3549492 Dose 2
Participants will receive LY3549492 orally
LY3549492
Administered orally
Placebo
Participants will receive placebo orally
Placebo
Administered orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LY3549492
Administered orally
Placebo
Administered orally
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have had a stable body weight for 3 months prior to screening
Exclusion Criteria
* Have:
* type 2 diabetes and on antidiabetic therapy (except type 2 diabetes being managed with diet and/or stable dose of metformin)
* rare forms of diabetes mellitus, or
* hemoglobin A1c (HbA1c) \>8%
* Have poorly controlled hypertension
* Have any of the following cardiovascular conditions within 12 months prior to screening:
* acute myocardial infarction
* stroke
* unstable angina, or
* hospitalization due to congestive heart failure.
* Have a history of New York Heart Association Functional Classification III or IV congestive heart failure
* Have signs and symptoms of liver disease
* Have a history of pancreatitis
* Have taken medications or alternative remedies for weight loss or weight gain within 3 months prior to screening
55 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Headlands Research - Scottsdale
Scottsdale, Arizona, United States
Valley Clinical Trials, Inc.
Covina, California, United States
Valley Clinical Trials, Inc.
Northridge, California, United States
Peninsula Research Associates
Rolling Hills Estates, California, United States
Artemis Institute for Clinical Research
San Diego, California, United States
JEM Research Institute
Atlantis, Florida, United States
Clinical Research Atlanta
Stockbridge, Georgia, United States
Great Lakes Clinical Trials - Andersonville
Chicago, Illinois, United States
Alliance for Multispecialty Research, LLC
Lexington, Kentucky, United States
Alliance for Multispecialty Research, LLC
Norman, Oklahoma, United States
Trial Management Associates
Myrtle Beach, South Carolina, United States
Viacar Recherche Clinique
Greenfield Park, , Canada
Apex Trials
Guelph, , Canada
OCT Research ULC
Kelowna, , Canada
Clinique Mémoire de Montréal
Montreal, , Canada
Ottawa Memory Clinic
Ottawa, , Canada
Richmond Clinical Trials
Richmond, , Canada
Q&T Research Sherbrooke Inc.
Sherbrooke, , Canada
Toronto Memory Program
Toronto, , Canada
BioPharma Services
Toronto, , Canada
Diex Recherche Trois-Rivieres
Trois-Rivières, , Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
J3H-MC-GZNI
Identifier Type: OTHER
Identifier Source: secondary_id
27357
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.